Ilaria Antonella Di Vico

Ilaria Antonella Di Vico

Auto-generated profile, based on publicly available information

Ilaria Antonella Di Vico

Azienda Ospedaliera Universitaria Integrata Verona Verona Italy

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2020 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
CGChristian Geroin
Christian Geroin
IVIlaria A. Di Vico
Ilaria A. Di Vico
GSGiovanna Squintani
Giovanna Squintani
ASAlessia Segatti
Alessia Segatti
TBTommaso Bovi
Tommaso Bovi
MTMichele Tinazzi
Michele Tinazzi

1 June 2024 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
MMMassimo Marano
Massimo Marano
CZCarmela Zizzo
Carmela Zizzo
MMMaria Chiara Malaguti
Maria Chiara Malaguti
RBRuggero Bacchin
Ruggero Bacchin
FCFrancesco Cavallieri
Francesco Cavallieri
Alessio Di FonzoAlessio Di Fonzo
Alessio Di Fonzo
Gaucher's disease (GD) is caused by biallelic mutations in the GBA1 gene, leading to reduced glucocerebrosidase (GCase) activity and substrate (glucosylceramide and glucosylsphingosine, GlcSph) accumulation. GBA1 variant carriers are at risk of Parkinson's disease (PD), but only those with biallelic mutations cross the threshold of GCase reduction, leading to substrate accumulation and GD. The link between GBA1 mutations, GD and PD is not fully understood. Here we aimed at reporting the results of a large PD population screening with dried blood spot tests for GD. We measured GCase activity and GlcSph levels in 1344 PD patients with dried blood spot tests, and performed GBA1 genetic sequencing. While the GCase activity was reduced in GBA1-PD carriers compared to wild type PD, GlcSph was increased in GBA1-PD compared to GBA1-controls, regardless of the underlying type of GBA1 variant. 13.6 % and 0.4 % of PD patients had mono- or biallelic GBA1 mutations respectively. GCase deficiency, lipid accumulation and clinical manifestations of GD was detected in five PD patients with biallelic GBA1 mutations, of whom four had a risk combined with a GD causing variant. GlcSph appearing higher in PD may represent a reliable biomarker of the disease and deserves to be further investigated. This study highlights the importance of screening PD patients for possible underlying GD, which is a treatable condition that should not be missed. We diagnosed GD cases carrying a "risk" variant in one allele, which is an unprecedented finding deserving further investigation.

1 May 2021 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
IVIlaria Antonella Di Vico
Ilaria Antonella Di Vico
Giovanni CirilloGiovanni Cirillo
Giovanni Cirillo
Alessandro TessitoreAlessandro Tessitore
Alessandro Tessitore
MSMattia Siciliano
Mattia Siciliano
MVMassimo Venturelli
Massimo Venturelli
MTMichele Tinazzi
Michele Tinazzi

30 April 2021 in NeuroRehabilitation
Verified
Journal Article
Closed access
PDF file
MGMarialuisa Gandolfi
Marialuisa Gandolfi
MRMarianna Riello
Marianna Riello
VBVeronica Bellamoli
Veronica Bellamoli
FBFederica Bombieri
Federica Bombieri
CGChristian Geroin
Christian Geroin
MTMichele Tinazzi
Michele Tinazzi
BACKGROUND: Rehabilitation has proven effective in improving motor symptoms (i.e., weakness, tremor, gait and balance disorders) in patients with Functional Motor Disorders (FMDs). Its effects on non-motor symptoms (NMSs) such as fatigue, pain, depression, anxiety and alexithymia, have not been explored yet. OBJECTIVE: To explore the effects of a validated inpatient 5-day rehabilitation program, followed by a home-based self-management plan on functional motor symptoms, NMSs, self-rated perception of change, and quality of life (QoL). METHODS: 33 FMD patients were enrolled. Measures for motor symptoms and NMSs were primary outcomes. Secondary outcomes included measures of self-perception of change and QoL. Patients were evaluated pre-treatment (T0), post-treatment (T1), and 3-month follow-up (T2). RESULTS: There was an overall significant decrease in functional motor symptoms, general, physical, and reduced-activity fatigue (for all, p < 0.001). Post hoc comparison showed significant improvements at T1, whereas effects remained significant at T2 for motor symptoms and physical fatigue. Gait and balance, alexithymia, and physical functioning (QoL) significantly improved at T2. More than 50% of patients reported marked improvement at T1 and T2. CONCLUSIONS: Our study suggests the benefits of rehabilitation and self-management plan on functional motor symptoms and physical fatigue in the medium-term. More actions are needed for the management of pain and other distressing NMSs in FMDs.

17 February 2021 in Acta Physiologica
Verified
Journal Article
Closed access
PDF file
CMCamilla Martignon
Camilla Martignon
FRFederico Ruzzante
Federico Ruzzante
GGGaia Giuriato
Gaia Giuriato
FLFabio Giuseppe Laginestra
Fabio Giuseppe Laginestra
APAnna Pedrinolla
Anna Pedrinolla
Massimo VenturelliMassimo Venturelli
Massimo Venturelli

15 August 2024 in European Journal of Neurology
Verified
Journal Article
Open access
TSTereza Serranova
Tereza Serranova
IVIlaria Di Vico
Ilaria Di Vico
MTMichele Tinazzi
Michele Tinazzi
SASelma Aybek
Selma Aybek
EBErvina Bilic
Ervina Bilic
JSJ. R. Stone
J. R. Stone
Background: Functional neurological disorder (FND) is a common cause of neurological disability. Despite recent advances in pathophysiological understanding and treatments, application of this knowledge to clinical practice is variable and limited.Objective: Our aim was to provide an expert overview of the state of affairs of FND practice across Europe, focusing on education and training, access to specialized care, reimbursement and disability policies, and academic and patient‐led representation of people with FND.Methods: We conducted a survey across Europe, featuring one expert per country. We asked experts to compare training and services for people with FND to those provided to people with multiple sclerosis (MS).Results: Responses from 25 countries revealed that only five included FND as a mandatory part of neurological training, while teaching about MS was uniformly included. FND was part of final neurology examinations in 3/17 countries, unlike MS that was included in all 17. Seventeen countries reported neurologists with an interest in FND but the estimated mean ratio of FND‐interested neurologists to MS neurologists was 1:20. FND coding varied, with psychiatric coding for FND impacting treatment access and disability benefits in the majority of countries. Twenty countries reported services refusing to see FND patients. Eight countries reported an FND special interest group or network; 11 reported patient‐led organizations.Conclusions: FND is largely a marginal topic within European neurology training and there is limited access to specialized care and disability benefits for people with FND across Europe. We discuss how this issue can be addressed at an academic, healthcare and patient organization level.